Searched for
GSK THERAPY
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- $10. 6 billion deal: GSK to buy US cancer specialist NuvalentBritish pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in c...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studiesGSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achievi...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Experimental pancreatic cancer drug appears to dramatically improve one year survival ratesA groundbreaking study published in Nature Medicine reveals that the experimental drug Elraglusib, when combined with standard chemotherapy...
- GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapyBritain's GSK is set to acquire RAPT Therapeutics for $2.2 billion. This move brings the experimental food allergy drug ozureprubart into G...
- GSK re-enters India’s cancer drug marketGlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gyna...
- GSK enters into oncology segment; launches therapies for gynaecological cancersGlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. Thes...
- GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billionGSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includ...
- GSK Pharma to expand into oncology, focus on adult vaccines in IndiaGlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and oncology in Indi...
- GSK boosts respiratory portfolio with $1.4 bn Aiolos Bio dealGSK will pay $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. It will also make milestone ...
- GSK India reports Rs 133 crore net profit in quarter four of FY23GSK India reported a net profit of Rs 133 crore for the quarter ended March 31, 2023, with continued momentum across general medicines and ...
- GSK to buy Canada's Bellus Health for $2 blnThe acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with ref...
- GSK-Vir therapy works against Omicron sub-variant, data suggestsBased on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain...
- GSK Pharma in search of buyer for non-core brandsFor one of the oldest multinational drug makers in the country, the growth curve has been challenging.
- Focus on 20 key brands to drive growth: GlaxoSmithKline pharmaceuticalsAs part of its growth plans the company is also planning to aggressively expand its field force.
- GSK Pharma: Investors must be careful of the competitive threats it faces in IndiaWhile the company's performance in the June quarter was strong sequentially, it will be interesting to see GSK's strategies to overcome the...
- GSK Pharma posts its lowest revenue growth at 3.3%GSK Pharma's March quarter performance reflected the company's failure to maintain its trajectory of recovery. At 3.3%, GSK Pharma has post...
- Cipla opposes patent for GSK’s cancer drugCipla has filed a grant opposition in the Kolkata patent office against GSK's newly-launched breast cancer drug on grounds of obviousness a...
Load More
